Breaking News Instant updates and real-time market news.

GWPH

GW Pharmaceuticals

$115.82

-0.37 (-0.32%)

08:02
04/21/17
04/21
08:02
04/21/17
08:02

GW Pharmaceuticals initiated with a Buy at Maxim

Maxim analyst Lauren Chung initiated GW Pharmaceuticals with a Buy rating and $135 price target, calling the company the "market leader" in cannabis therapeutics with a first-mover advantage in epilepsy.

GWPH GW Pharmaceuticals
$115.82

-0.37 (-0.32%)

12/05/16
CANT
12/05/16
NO CHANGE
Target $208
CANT
Buy
GW Pharmaceuticals price target raised after Epidiolex data at Cantor
Cantor analyst Elemer Piros raised his price target for GW Pharmaceuticals to $208 from $182 following its Epidiolex data presented at the American Epilepsy Society meeting. The analyst believes the data illustrates "robustness and remarkable consistency" across two distinct forms of epilepsy, Lennox Gastaut and Dravet syndrome and notes that the company laid to rest the largely overblown concern regarding drug interaction with clobazam. Piros believes GW Pharmaceuticals is in "good shape" for a New Drug Application covering both indications by the end of 1H17, and reiterates a Buy rating on the shares.
02/07/17
CANT
02/07/17
NO CHANGE
Target $208
CANT
Overweight
GW Pharmaceuticals Phase 2 data 'very encouraging,' says Cantor
Cantor Fitzgerald analyst Elemer Piros believes GW Pharmaceuticals' Phase 2 glioblastoma multiforme data today are "very encouraging" and further support of the "multi-potent effect of cannabinoid-based medicines across an array of neurological condition." The analyst reiterates a Buy rating on GW shares with a $208 price target. The stock in early trading is up 93c to $121.69.
02/07/17
PIPR
02/07/17
NO CHANGE
Target $147
PIPR
Overweight
Piper says GW Pharmaceuticals remains on track with Epidiolex
Piper Jaffray analyst Joshua Schimmer said GW Pharmaceuticals remains on track to potentially launch Epidiolex for Dravet Syndrome and LGS in the first half of 2018 and he sees the company's expanded access program and ongoing trials positioning the product for a "robust launch" upon approval. Retention of patients on therapy remains "exceptionally high," added the analyst, who calls GW a top mid-cap pick citing his confidence in the commercial outlook for Epidiolex and optimism about its pipeline. Schimmer keeps an Overweight rating and $147 price target on GW Pharma shares.
03/02/17
JANY
03/02/17
NO CHANGE
Target $55
JANY
Sell
GW Pharmaceuticals expectations, valuation remain too high, says Janney Capital
Janney Capital analyst Ken Trbovich raised his estimates for GW Pharmaceuticals and increased his fair value estimate for the shares to $55, citing the "excitement" he heard among physicians who regularly treat patients with Epidiolex during the Annual Epilepsy Society meeting last December. However, he continues to think regulatory and commercial challenges will likely prevent Epidiolex from achieving high expectations set by the market, even if the drug is approved on first review for Dravet Syndrome and LGS and the subsequent studies in infantile spasm and tuberous sclerosis succeed. Trbovich, who notes that consensus estimates call for Epidiolex to hit $900M in sales in just 3-4 years even though the most recent FDA-approved drugs for orphan epilepsy indications had sales in the range of $100M-$300M 4-8 years after launch, keeps a Sell rating on GW shares.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$243.60

2.27 (0.94%)

, SPX

S&P 500

15:23
06/28/17
06/28
15:23
06/28/17
15:23
General news
Senate Intelligence Committee to receive Comey memos, Politico says »

Senate Intelligence…

SPY

SPDR S&P 500 ETF Trust

$243.60

2.27 (0.94%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
06/28/17
06/28
15:17
06/28/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
06/28/17
06/28
15:16
06/28/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLCO

Melco Resorts & Entertainment

$22.71

-0.29 (-1.26%)

15:10
06/28/17
06/28
15:10
06/28/17
15:10
Options
Melco Resorts with a bullish short-term option play »

Melco Resorts with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
06/28/17
06/28
15:05
06/28/17
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

SIEGY

Siemens

$70.08

-0.19 (-0.27%)

, BDRBF

Bombardier

$1.83

-0.0236 (-1.27%)

15:02
06/28/17
06/28
15:02
06/28/17
15:02
Periodicals
Breaking Periodicals news story on Siemens, Bombardier »

Siemens, Bombardier…

SIEGY

Siemens

$70.08

-0.19 (-0.27%)

BDRBF

Bombardier

$1.83

-0.0236 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

T

AT&T

$37.89

0.186 (0.49%)

15:00
06/28/17
06/28
15:00
06/28/17
15:00
Options
AT&T attracts downside put buyers »

AT&T attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POT

Potash

$16.34

-0.015 (-0.09%)

14:55
06/28/17
06/28
14:55
06/28/17
14:55
Options
Potash put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARA

Cara Therapeutics

$26.42

1.01 (3.97%)

, NKTR

Nektar

$18.82

-0.915 (-4.64%)

14:46
06/28/17
06/28
14:46
06/28/17
14:46
Hot Stocks
Before the Move: Watch Cara Therapeutics into osteoarthritis pain results »

Cara Therapeutics (CARA)…

CARA

Cara Therapeutics

$26.42

1.01 (3.97%)

NKTR

Nektar

$18.82

-0.915 (-4.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

NRG

NRG Energy

$17.41

0.2001 (1.16%)

14:45
06/28/17
06/28
14:45
06/28/17
14:45
Options
NRG Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDEN

Golden Entertainment

$20.36

-0.37 (-1.78%)

14:43
06/28/17
06/28
14:43
06/28/17
14:43
Hot Stocks
Golden Entertainment announces approval for Illinois gaming terminal license »

Golden Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

Labarge

$54.33

-0.085 (-0.16%)

14:30
06/28/17
06/28
14:30
06/28/17
14:30
Options
6X average daily volume in L Brands driven by a three-way spread »

6X average daily volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENX

Fenix Parts

$1.57

0.08 (5.37%)

14:29
06/28/17
06/28
14:29
06/28/17
14:29
Hot Stocks
Fenix Parts plunges after Nasdaq delisting notice »

Shares of microcap Fenix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:28
06/28/17
06/28
14:28
06/28/17
14:28
Hot Stocks
Breaking Hot Stocks news story on Hecla Mining »

Hecla Mining trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPH

KemPharm

$3.45

0.05 (1.47%)

14:25
06/28/17
06/28
14:25
06/28/17
14:25
Conference/Events
KemPharm to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:24
06/28/17
06/28
14:24
06/28/17
14:24
Earnings
Hecla Mining sees Q2 revenue of $127M-$137M, consensus $145.85M »

Hecla Mining announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.25

0.075 (1.45%)

14:21
06/28/17
06/28
14:21
06/28/17
14:21
Hot Stocks
Hecla Mining to offer $500M of senior notes »

Hecla Mining announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVA

Sinovac Biotech

$6.34

-0.07 (-1.09%)

14:20
06/28/17
06/28
14:20
06/28/17
14:20
Hot Stocks
Sinobioway Consortium confirms Sinovac Biotech offer raised to $8 per share »

Shandong Sinobioway…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
06/28/17
06/28
14:17
06/28/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
06/28/17
06/28
14:16
06/28/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

PowerShares QQQ Trust

$138.03

-2.55 (-1.81%)

14:10
06/28/17
06/28
14:10
06/28/17
14:10
Options
Defensive option play in the PowerShares QQQ »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGX

Argan

$62.40

0.9 (1.46%)

14:08
06/28/17
06/28
14:08
06/28/17
14:08
Initiation
Argan initiated  »

Argan initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HL

Hecla Mining

$5.24

0.07 (1.35%)

14:05
06/28/17
06/28
14:05
06/28/17
14:05
Hot Stocks
Breaking Hot Stocks news story on Hecla Mining »

Hecla Mining trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
06/28/17
06/28
14:05
06/28/17
14:05
General news
U.S. equities are extending their bull run »

U.S. equities are…

14:00
06/28/17
06/28
14:00
06/28/17
14:00
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.